文献速递临床试验与 GCP流行病学与生物统计

PRolaCT研究:泌乳素瘤联合随机对照试验与观察性队列研究方案

The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma.
PubMed 文献 · Trials · 2021-09-25

该研究方案包含三项非盲随机对照试验(PRolaCT-1/2/3)及一个观察性队列(PRolaCT-O),比较神经外科咨询及后续内镜经蝶窦腺瘤切除与当前标准药物治疗(多巴胺激动剂)在非侵袭性泌乳素瘤(<25mm)患者中的效果。主要结局为36个月后疾病缓解和12个月后健康相关生活质量。

要点

  • PRolaCT-1纳入新诊断未治疗患者,PRolaCT-2为DA治疗4-6个月者,PRolaCT-3为DA治疗>2年持续存在者。
  • PRolaCT-O纳入拒绝随机化且有明确治疗偏好的患者。
  • 主要结局为36个月缓解率和12个月健康相关生活质量。

核心结论

  • 早期或 upfront 手术切除可能成为有限大小非侵袭性泌乳素瘤患者除多巴胺激动剂治疗外的合理替代方案。

研究设计与样本

  • 联合随机对照试验与观察性队列研究设计,包含三项非盲随机对照试验(PRolaCT-1、PRolaCT-2、PRolaCT-3)和一个观察性研究臂(PRolaCT-O)。
  • 纳入非侵袭性泌乳素瘤(<25 mm)患者,根据多巴胺激动剂治疗时长分配至不同随机对照试验。

主要发现

  • 原文未报告研究结果,仅描述研究方案。

关键数值与推荐

  • PRolaCT-1:新诊断、未治疗患者;PRolaCT-2:多巴胺激动剂治疗4-6个月;PRolaCT-3:多巴胺激动剂治疗>2年后持续存在泌乳素瘤。
  • 主要结局:36个月后疾病缓解和12个月后健康相关生活质量。

临床怎么用

  • 研究将收集随机化和观察性数据,可能促进更个体化的循证医学实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many patients require prolonged DA treatment, while side effects negatively impact health-related quality of life (HRQoL). Endoscopic transsphenoidal resection is reserved for patients with severe side effects, or with DA-resistant prolactinoma. Surgery has a good safety profile and high probability of remission and may thus deserve a more prominent place in prolactinoma treatment. The hypothesis for this study is that early or upfront surgical resection is superior to DA treatment both in terms of HRQoL and remission rate in patients with a non-invasive prolactinoma of limited size. METHODS: We present a combined randomised clinical trial and observational cohort study design, which comprises three unblinded randomised controlled trials (RCTs; PRolaCT-1, PRolaCT-2, PRolaCT-3), and an observational study arm (PRolaCT-O) that compare neurosurgical counselling, and potential subsequent endoscopic transsphenoidal adenoma resection, with current standard care. Patients with a non-invasive prolactinoma (< 25 mm) will be eligible for one of three RCTs based on the duration of pre-treatment with DAs: PRolaCT-1: newly diagnosed, treatment-naïve patients; PRolaCT-2: patients with limited duration of DA treatment (4-6 months); and PRolaCT-3: patients with persisting prolactinoma after DA treatment for > 2 years. PRolaCT-O will include patients who decline randomisation, due to e.g. a clear treatment preference. Primary outcomes are disease remission after 36 months and HRQoL after 12 months. DISCUSSION: Early or upfront surgical resection for patients with a limited-sized prolactinoma may be a reasonable alternative to the current standard practice of DA treatment, which we will investigate in three RCTs and an observational cohort study. Within the three RCTs, patients will be randomised between neurosurgical counselling and standard care. The observational study arm will recruit patients who refuse randomisation and have a pronounced treatment preference. PRolaCT will collect randomised and observational data, which may facilitate a more individually tailored practice of evidence-based medicine. TRIAL REGISTRATION: US National Library of Medicine registry (ClinicalTrials.gov) NCT04107480 . Registered on 27 September 2019, registered retrospectively (by 2 months).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zandbergen IM, Zamanipoor Najafabadi AH, Pelsma ICM, et al. The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. Trials. 2021. PMID: 34563236. doi:10.1186/s13063-021-05604-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。